These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24692038)

  • 21. [RSV-prophylaxis--to whom?].
    Lossius K
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2494. PubMed ID: 11070982
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab.
    Lavoie PM; Solimano A; Taylor R; Kwan E; Claydon J; Turvey SE; Marr N
    JAMA Pediatr; 2016 Feb; 170(2):174-6. PubMed ID: 26720836
    [No Abstract]   [Full Text] [Related]  

  • 24. Translational sciences approach to RSV vaccine development.
    Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
    Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS; Chen X; Kumar VR
    Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 28. Palivizumab prophylaxis in preterm infants.
    Tang PK
    Lancet Respir Med; 2017 Mar; 5(3):171. PubMed ID: 28219614
    [No Abstract]   [Full Text] [Related]  

  • 29. Palivizumab and emerging therapies for respiratory syncytial virus.
    Hoopes JM; Makari D; Groothuis J
    Expert Opin Biol Ther; 2012 May; 12(5):547-8; author reply 549. PubMed ID: 22348302
    [No Abstract]   [Full Text] [Related]  

  • 30. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
    Mitchell I
    South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
    [No Abstract]   [Full Text] [Related]  

  • 31. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to respiratory synctial virus.
    Hampp C; Winterstein AG
    South Med J; 2008 Feb; 101(2):212-3; author reply 213-4. PubMed ID: 18364631
    [No Abstract]   [Full Text] [Related]  

  • 33. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis for respiratory syncytial virus bronchiolitis.
    Nadal D; Berger C; Aebi C; Kind C
    Lancet; 1999 Dec; 354(9194):1997. PubMed ID: 10622321
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.
    Paes B; Lanctôt K
    Turk J Pediatr; 2013; 55(5):564-7. PubMed ID: 24382545
    [No Abstract]   [Full Text] [Related]  

  • 36. Palivizumab prophylaxis during respiratory syncytial virus outbreak in the neonatal intensive care unit.
    Alan S; Cakır U; Erdeve O; Atasay B; Arsan S
    Turk J Pediatr; 2013; 55(2):237-8. PubMed ID: 24192692
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams].
    Korbal P; Mikołajczak A; Szymański W
    Ginekol Pol; 2003 Oct; 74(10):1154-9. PubMed ID: 14669411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey: author's reply.
    Oncel MY; Alyamaç-Dizdar E; Erdeve O; Oğuz S; Dilmen U
    Turk J Pediatr; 2013; 55(5):568. PubMed ID: 24401320
    [No Abstract]   [Full Text] [Related]  

  • 39. Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply.
    Oncel MY; Dizdar EA; Dilmen U
    Turk J Pediatr; 2013; 55(2):239. PubMed ID: 24205516
    [No Abstract]   [Full Text] [Related]  

  • 40. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.